Malaria Clinical Trial
Official title:
Cluster Randomized Trial of Malaria Seasonal IPTc Combined With Community Case Management in Saraya District, SE Senegal
Malaria is a major public health problem. 250 million cases annually leads to approximately
1 million deaths. Over 80 per cent of these deaths occur among African children under age
five. The main interventions covered treatment with Artemisinin Combination Therapies (ACT),
long lasting bednets distribution and Rapid Diagnosis Tests (RDT) to improve malaria
diagnosis. This has led in Senegal to a substantial decrease in the incidence of malaria, in
2009. However the recent overall decline hides the fact that malaria incidence remains very
high in the south of Senegal. That's why Home-based management (HMM) for malaria is being
introduced in selected areas. Intermittent Preventive Treatment (IPT) by monthly
administration of a therapeutic dose of antimalarials can achieve a very high degree of
protection from attacks of clinical malaria in children. The purpose of this project is to
evaluate the effectiveness of combining IPTc with HMM in southern Senegal
The study objectives are to :
- Assess the tolerance of IPTc using SP+AQ when it is administered for a longer period in
areas with a longer transmission season,
- Assess the added benefit that IPT with the association of Sulfadoxine-Pyrimethamine +
Amodiaquine can offer in populations where a rapid and early care with home management
of malaria is already established.
- Determine the cost benefit ratio of the addition of IPTc with HMM. A cluster randomized
controlled trial has been designed to evaluate the effectiveness of adding seasonal
IPTc with sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ) for 5 months per year, in
villages where home-based management of malaria is implemented. All villages in Saraya
district, excluding 7 villages with a health post, will be eligible to participate.
Saraya villages will be combined to form 24 clusters which will be randomized to
receive HMM from a community volunteer, or IPTc plus HMM. Trained volunteer Community
Medicine Distributors (CMD) will provide HMM. The primary endpoint will be the
incidence of clinical malaria with fever or history of fever and parasitaemia with
density of at least 3000/ul. Secondary outcomes will include the safety, the
tolerability, the coverage and acceptability of the intervention. Both the recurrent
and capital costs to the health service of training staff and delivering the
interventions will be estimated. Both direct and indirect costs to users of the
services (children and their families) will also be assessed.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |